NCT03391778

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: USWM CT, LLC · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Detailed description

Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

Conditions

• Neoplasms

Interventions

Type	Name	Description
BIOLOGICAL	ADP adoptive cell therapy	No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Timeline

• Start date: 2018-04-09
• Primary completion: 2032-04-01
• Completion: 2032-04-01
• First posted: 2018-01-05
• Last updated: 2026-03-03

Locations

24 sites across 8 countries: United States, Australia, Canada, Germany, Italy, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study